Literature DB >> 24419204

Viral cyclin promotes KSHV-induced cellular transformation and tumorigenesis by overriding contact inhibition.

Tiffany Jones1, Suzane Ramos da Silva2, Roble Bedolla3, Fengchun Ye3, Fuchun Zhou3, Shou-Jiang Gao4.   

Abstract

Kaposi sarcoma-associated herpesvirus (KSHV) is a tumor virus encoding several proto-oncogenes. However, the roles of these viral genes in KSHV-induced tumorigenesis have not been defined. In this study, we used a recently developed model of KSHV-induced cellular transformation and tumorigenesis combining with a reverse genetic system to examine the role of a KSHV latent gene vCyclin (ORF72), a cellular Cyclin D2 homolog, in KSHV-induced oncogenesis. Deletion of vCyclin did not affect cell proliferation and cell cycle progression at a low-density condition, when cells were at an active proliferation state. However, vCyclin mutant cells were contact-inhibited and arrested at G 1 phase at a high-density condition. As a result, vCyclin mutant cells formed less and smaller colonies in soft agar assay. Nude mice inoculated with vCyclin mutant cells had reduced tumor incidence and extended tumor latency and survival compared with mice inoculated with wild-type (WT) virus-infected cells. WT but not mutant virus effectively induced Cyclin-dependent kinase inhibitor p27/Kip1 Ser10 phosphorylation and cytoplasmic relocalization. shRNA knockdown of p27 released the blockage of the mutant cells from cell cycle arrest at G 1 phase at a high-density condition. Together, these results indicate that vCyclin primarily functions to enhance cellular transformation and tumorigenesis by promoting cell cycle progression and cell proliferation at a contact-inhibited condition.

Entities:  

Keywords:  KSHV; Kaposi sarcoma; cell cycle progression; cell proliferation; cellular transformation; contact inhibition; p27/Kip1; tumorigenesis; vCyclin/ORF72

Mesh:

Substances:

Year:  2014        PMID: 24419204      PMCID: PMC3979920          DOI: 10.4161/cc.27758

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  50 in total

1.  Phosphorylation at serine 10, a major phosphorylation site of p27(Kip1), increases its protein stability.

Authors:  N Ishida; M Kitagawa; S Hatakeyama; K Nakayama
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

2.  The N-terminal peptide of the Kaposi's sarcoma-associated herpesvirus (KSHV)-cyclin determines substrate specificity.

Authors:  Philipp Kaldis
Journal:  J Biol Chem       Date:  2005-01-21       Impact factor: 5.157

3.  Subversion of autophagy by Kaposi's sarcoma-associated herpesvirus impairs oncogene-induced senescence.

Authors:  Andrew M Leidal; David P Cyr; Richard J Hill; Patrick W K Lee; Craig McCormick
Journal:  Cell Host Microbe       Date:  2012-02-16       Impact factor: 21.023

4.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo.

Authors:  G P Dimri; X Lee; G Basile; M Acosta; G Scott; C Roskelley; E E Medrano; M Linskens; I Rubelj; O Pereira-Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

5.  Novel properties of the cyclin encoded by Human Herpesvirus 8 that facilitate exit from quiescence.

Authors:  E S Child; D J Mann
Journal:  Oncogene       Date:  2001-06-07       Impact factor: 9.867

6.  Regulation of tumor necrosis factor-like weak inducer of apoptosis receptor protein (TWEAKR) expression by Kaposi's sarcoma-associated herpesvirus microRNA prevents TWEAK-induced apoptosis and inflammatory cytokine expression.

Authors:  Johanna R Abend; Thomas Uldrick; Joseph M Ziegelbauer
Journal:  J Virol       Date:  2010-09-15       Impact factor: 5.103

7.  The oncogenic potential of Kaposi's sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo.

Authors:  Emmy W Verschuren; Juha Klefstrom; Gerard I Evan; Nic Jones
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

8.  The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma.

Authors:  Farnaz D Fakhari; Joseph H Jeong; Yogita Kanan; Dirk P Dittmer
Journal:  J Clin Invest       Date:  2006-02-23       Impact factor: 14.808

9.  Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus.

Authors:  D J Mann; E S Child; C Swanton; H Laman; N Jones
Journal:  EMBO J       Date:  1999-02-01       Impact factor: 11.598

10.  Kaposi's sarcoma herpesvirus microRNAs target caspase 3 and regulate apoptosis.

Authors:  Guillaume Suffert; Georg Malterer; Jean Hausser; Johanna Viiliäinen; Aurélie Fender; Maud Contrant; Tomi Ivacevic; Vladimir Benes; Frédéric Gros; Olivier Voinnet; Mihaela Zavolan; Päivi M Ojala; Juergen G Haas; Sébastien Pfeffer
Journal:  PLoS Pathog       Date:  2011-12-08       Impact factor: 6.823

View more
  17 in total

1.  Oncogenic Kaposi's Sarcoma-Associated Herpesvirus Upregulates Argininosuccinate Synthase 1, a Rate-Limiting Enzyme of the Citrulline-Nitric Oxide Cycle, To Activate the STAT3 Pathway and Promote Growth Transformation.

Authors:  Tingting Li; Ying Zhu; Fan Cheng; Chun Lu; Jae U Jung; Shou-Jiang Gao
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

Review 2.  More than just oncogenes: mechanisms of tumorigenesis by human viruses.

Authors:  Marta M Gaglia; Karl Munger
Journal:  Curr Opin Virol       Date:  2018-09-27       Impact factor: 7.090

3.  An endothelial cell line infected by Kaposi's sarcoma-associated herpes virus (KSHV) allows the investigation of Kaposi's sarcoma and the validation of novel viral inhibitors in vitro and in vivo.

Authors:  Tatyana Dubich; Anna Lieske; Susann Santag; Guillaume Beauclair; Jessica Rückert; Jennifer Herrmann; Jan Gorges; Guntram Büsche; Uli Kazmaier; Hansjörg Hauser; Marc Stadler; Thomas F Schulz; Dagmar Wirth
Journal:  J Mol Med (Berl)       Date:  2019-01-04       Impact factor: 4.599

4.  Molecular Biology of KSHV in Relation to HIV/AIDS-Associated Oncogenesis.

Authors:  Meilan He; Fan Cheng; Suzane Ramos da Silva; Brandon Tan; Océane Sorel; Marion Gruffaz; Tingting Li; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2019

5.  SIRT1 and AMPK pathways are essential for the proliferation and survival of primary effusion lymphoma cells.

Authors:  Meilan He; Brandon Tan; Karthik Vasan; Hongfeng Yuan; Fan Cheng; Suzane Ramos da Silva; Chun Lu; Shou-Jiang Gao
Journal:  J Pathol       Date:  2017-05-13       Impact factor: 7.996

6.  Viral interleukin-6 encoded by an oncogenic virus promotes angiogenesis and cellular transformation by enhancing STAT3-mediated epigenetic silencing of caveolin 1.

Authors:  Wan Li; Qingxia Wang; Xiaoyu Qi; Yuanyuan Guo; Hongmei Lu; Yuheng Chen; Zhongmou Lu; Qin Yan; Xiaofei Zhu; Jae U Jung; Giovanna Tosato; Shou-Jiang Gao; Chun Lu
Journal:  Oncogene       Date:  2020-05-11       Impact factor: 9.867

7.  TLR4-Mediated Inflammation Promotes KSHV-Induced Cellular Transformation and Tumorigenesis by Activating the STAT3 Pathway.

Authors:  Marion Gruffaz; Karthik Vasan; Brandon Tan; Suzane Ramos da Silva; Shou-Jiang Gao
Journal:  Cancer Res       Date:  2017-10-19       Impact factor: 12.701

8.  Oncogenic herpesvirus KSHV Hijacks BMP-Smad1-Id signaling to promote tumorigenesis.

Authors:  Deguang Liang; Hao Hu; Shasha Li; Jiazhen Dong; Xing Wang; Yuhan Wang; Li He; Zhiheng He; Yuan Gao; Shou-Jiang Gao; Ke Lan
Journal:  PLoS Pathog       Date:  2014-07-10       Impact factor: 6.823

9.  HIV-1 Nef and KSHV oncogene K1 synergistically promote angiogenesis by inducing cellular miR-718 to regulate the PTEN/AKT/mTOR signaling pathway.

Authors:  Min Xue; Shuihong Yao; Minmin Hu; Wan Li; Tingting Hao; Feng Zhou; Xiaofei Zhu; Hongmei Lu; Di Qin; Qin Yan; Jianzhong Zhu; Shou-Jiang Gao; Chun Lu
Journal:  Nucleic Acids Res       Date:  2014-08-07       Impact factor: 16.971

10.  An Oncogenic Virus Promotes Cell Survival and Cellular Transformation by Suppressing Glycolysis.

Authors:  Ying Zhu; Suzane Ramos da Silva; Meilan He; Qiming Liang; Chun Lu; Pinghui Feng; Jae U Jung; Shou-Jiang Gao
Journal:  PLoS Pathog       Date:  2016-05-17       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.